TY  - CHAP
M1  - Book, Section
TI  - Tacrolimus
A1  - Bauer, Larry A.
Y1  - 2015
N1  - 
T2  - Applied Clinical Pharmacokinetics, 3e
AB  - Tacrolimus  (also  known  as  FK506)  is  a  macrolide-based  calcineurin  inhibitor,  with  immunosuppressant  actions,  that  is  used  for  the  prevention  of  graft  rejection  in  solid  organ  transplant  patients.1  Currently,  it  is  approved  for  use  in  heart,  liver,  and  renal  transplant  patients.  It  is  also  used  in  lung,  heart-lung,  and  other  solid  organ  transplant  recipients,  as  well  as  the  treatment  of  graft-versus-host  disease  in  hematopoietic  stem  cell  transplant  patients.1,2  The  immunomodulating  effects  of  tacrolimus  are  due  to  its  ability  to  block  the  production  of  interleukin-2  and  other  cytokines  produced  by  T  lymphocytes.1,2,  and  3  Tacrolimus  binds  to  FK-binding  protein-12  (FKPB-12),  an  intracellular  cytoplasmic  protein  found  in  T  cells.  The  tacrolimus-FKPB  complex  interacts  with  calcineurin,  inhibits  the  catalytic  activity  of  calcineurin,  and  blocks  the  production  of  intermediaries  involved  with  the  expression  of  genes  regulating  the  production  of  cytokines.  
SN  - 
PB  - McGraw-Hill Medical
CY  - New York, NY
Y2  - 2024/04/19
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=1106304380
ER  -